Advertisement
The Cure King brand is currently comprised of 26 products in threecategories of Western and traditional Chinese medicines ("TCM"). The firstcategory includes eight injectable medicines aimed at treating diarrhea,mastitis, secondary infections caused by viruses, respiratory infections, lossof appetite and other infectious diseases in pigs. The second category has 11products in powder form that address intestinal infections, respiratoryinfections and diseases in young birds, as well as coccidiosis, ovaritis andnutrient-deficient diseases in chickens. The third category includes sevencompound TCMs that focus on treating diarrhea, viral infections, slowgastrointestinal movements and colds in livestock. All 26 medicines have beenapproved by the Ministry of Agriculture for GMP-certified production. Skystarplans to increase its Cure King portfolio to meet ongoing market demand basedon market response and disease cycles.
Advertisement
"Based on nationwide market research, we have found certain diseases to beprevalent in livestock. A unified brand targeting the treatment of thesediseases is precisely what the market needs given the lack of consistency andnumber of inferior medicines on the market. We are committed to addressingthis unmet need and enhancing our market penetration by providing reliable,effective and quality treatments," commented Mr. Weibing Lu, CEO and Chairmanof Skystar.
Skystar will market the Cure King line through regular advertisements inmajor trade publications along with a brochure that contains in-depthinformation on a variety of common diseases and specific instructions for theappropriate treatments. The Company also provides seminars in local villagesto educate farmers on diagnosing and treating various livestock aliments. CureKing is a registered trademark brand.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company is a China-based producer anddistributor of vaccines, microorganisms and veterinary medication to cure andprevent disease in poultry, livestock, birds and pets. The Company's productline consists of more than 100 products with over 50 additional products inthe developmental stage. Skystar has formed strategic sales distributionnetworks throughout China. The Company recently completed construction of newstate-of-the-art bio-pharmaceutical facilities covering an area of almosteight acres. The new facilities meet or exceed all Good Manufacturing Practice(GMP) Certification Standards and have received GMP Certification from theChinese government. For additional information, please visithttp://www.skystarbio-pharmaceutical.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: This press release contains certain "forward-looking statements," asdefined in the United States Private Securities Litigation Reform Act of 1995,that involve a number of risks and uncertainties. Forward-looking statementsare statements that are not historical facts. Such forward-looking statementsare based upon the current beliefs and expectations of management and aresubject to risks and uncertainties, which could cause actual results to differfrom the forward-looking statements. Such factors include, but are not limitedto the Company's ability to develop new products, market acceptance of thecompany's new products, ability to obtain the regulatory approvals orclearances that are necessary to commercialize its products, ability toprotect proprietary rights, political and economic factors in the People'sRepublic of China and other factors detailed from time to time in theCompany's filings with the United States Securities and Exchange Co
